Editas Medicine Analyst Ratings
Editas Medicine Analyst Ratings
Editas 醫學分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/18/2023 | 13.8% | JP Morgan | → $8 | Upgrades | Underweight → Neutral |
| 10/17/2023 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 09/29/2023 | 141.82% | Stifel | $9 → $17 | Upgrades | Hold → Buy |
| 09/13/2023 | 99.15% | Cantor Fitzgerald | → $14 | Reiterates | Overweight → Overweight |
| 08/29/2023 | 99.15% | Cantor Fitzgerald | → $14 | Reiterates | Overweight → Overweight |
| 08/03/2023 | 70.7% | Oppenheimer | → $12 | Reiterates | Perform → Perform |
| 08/03/2023 | 170.27% | Chardan Capital | $22 → $19 | Maintains | Buy |
| 06/13/2023 | 113.37% | Cantor Fitzgerald | → $15 | Reiterates | Overweight → Overweight |
| 06/13/2023 | 141.82% | Raymond James | → $17 | Upgrades | Market Perform → Outperform |
| 05/09/2023 | 70.7% | Oppenheimer | → $12 | Reiterates | → Perform |
| 05/08/2023 | 13.8% | RBC Capital | $7 → $8 | Maintains | Sector Perform |
| 05/08/2023 | 99.15% | Credit Suisse | $15 → $14 | Maintains | Neutral |
| 05/08/2023 | 212.94% | Chardan Capital | → $22 | Reiterates | → Buy |
| 02/23/2023 | 113.37% | Credit Suisse | $13 → $15 | Maintains | Neutral |
| 02/23/2023 | 212.94% | Chardan Capital | $35 → $22 | Maintains | Buy |
| 02/23/2023 | 42.25% | RBC Capital | $14 → $10 | Maintains | Sector Perform |
| 02/01/2023 | 113.37% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 01/24/2023 | -0.43% | Morgan Stanley | $8 → $7 | Maintains | Underweight |
| 01/23/2023 | -0.43% | SVB Leerink | $6 → $7 | Maintains | Market Perform |
| 01/10/2023 | -14.65% | SVB Leerink | $7 → $6 | Maintains | Market Perform |
| 01/04/2023 | 412.09% | Wells Fargo | $50 → $36 | Maintains | Overweight |
| 12/13/2022 | 56.47% | Citigroup | → $11 | Initiates Coverage On | → Neutral |
| 12/06/2022 | 84.92% | Credit Suisse | → $13 | Assumes | → Neutral |
| 11/18/2022 | 113.37% | B of A Securities | $18 → $15 | Maintains | Neutral |
| 11/18/2022 | 397.87% | Truist Securities | $80 → $35 | Maintains | Buy |
| 11/18/2022 | 156.05% | Baird | $25 → $18 | Maintains | Outperform |
| 11/18/2022 | 13.8% | Morgan Stanley | $10 → $8 | Maintains | Underweight |
| 11/18/2022 | 99.15% | RBC Capital | $32 → $14 | Maintains | Sector Perform |
| 11/18/2022 | 70.7% | Oppenheimer | $28 → $12 | Downgrades | Outperform → Perform |
| 11/18/2022 | 84.92% | Credit Suisse | $25 → $13 | Downgrades | Outperform → Neutral |
| 11/18/2022 | 397.87% | Chardan Capital | $43 → $35 | Maintains | Buy |
| 11/17/2022 | -0.43% | SVB Leerink | $14 → $7 | Maintains | Market Perform |
| 11/08/2022 | 42.25% | Morgan Stanley | $15 → $10 | Maintains | Underweight |
| 11/03/2022 | 355.19% | RBC Capital | $40 → $32 | Maintains | Sector Perform |
| 11/03/2022 | 255.62% | Baird | $30 → $25 | Maintains | Outperform |
| 11/03/2022 | 511.66% | Chardan Capital | $60 → $43 | Maintains | Buy |
| 11/03/2022 | 70.7% | SVB Leerink | $14 → $12 | Maintains | Market Perform |
| 09/29/2022 | 156.05% | B of A Securities | → $18 | Initiates Coverage On | → Neutral |
| 08/04/2022 | 141.82% | Barclays | $16 → $17 | Maintains | Equal-Weight |
| 05/24/2022 | 13.8% | Goldman Sachs | $10 → $8 | Maintains | Sell |
| 05/09/2022 | 113.37% | Morgan Stanley | $17 → $15 | Maintains | Underweight |
| 04/12/2022 | 141.82% | Morgan Stanley | $16 → $17 | Maintains | Underweight |
| 02/25/2022 | 682.36% | Oppenheimer | $80 → $55 | Maintains | Outperform |
| 02/25/2022 | 753.49% | Chardan Capital | $75 → $60 | Maintains | Buy |
| 02/25/2022 | 284.07% | SVB Leerink | $41 → $27 | Maintains | Market Perform |
| 01/06/2022 | 241.39% | Morgan Stanley | $37 → $24 | Maintains | Underweight |
| 10/19/2021 | 483.21% | SVB Leerink | → $41 | Initiates Coverage On | → Market Perform |
| 09/24/2021 | 824.61% | Stifel | → $65 | Initiates Coverage On | → Hold |
| 09/10/2021 | 1037.98% | Oppenheimer | $42 → $80 | Upgrades | Perform → Outperform |
| 08/09/2021 | 1037.98% | Truist Securities | $45 → $80 | Upgrades | Hold → Buy |
| 08/05/2021 | 753.49% | Evercore ISI Group | $20 → $60 | Upgrades | Underperform → Outperform |
| 05/10/2021 | 426.32% | Morgan Stanley | $40 → $37 | Maintains | Underweight |
| 05/04/2021 | 468.99% | RBC Capital | → $40 | Initiates Coverage On | → Sector Perform |
| 04/16/2021 | 184.5% | Goldman Sachs | → $20 | Initiates Coverage On | → Sell |
| 03/22/2021 | 725.04% | Credit Suisse | → $58 | Initiates Coverage On | → Outperform |
| 03/02/2021 | 468.99% | Morgan Stanley | $45 → $40 | Maintains | Underweight |
| 03/01/2021 | 554.34% | Barclays | → $46 | Downgrades | Overweight → Equal-Weight |
| 02/26/2021 | 540.11% | Truist Securities | → $45 | Downgrades | Buy → Hold |
| 02/10/2021 | 995.31% | Chardan Capital | $55 → $77 | Maintains | Buy |
| 01/19/2021 | 540.11% | Morgan Stanley | $64 → $45 | Downgrades | Equal-Weight → Underweight |
| 01/08/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 12/16/2020 | 810.38% | Morgan Stanley | $30 → $64 | Maintains | Equal-Weight |
| 12/10/2020 | 881.51% | Wells Fargo | $28 → $69 | Upgrades | Equal-Weight → Overweight |
| 11/11/2020 | 326.74% | Morgan Stanley | $31 → $30 | Maintains | Equal-Weight |
| 11/06/2020 | 753.49% | Raymond James | $65 → $60 | Maintains | Outperform |
| 11/03/2020 | 99.15% | Baird | → $14 | Initiates Coverage On | → Underperform |
| 10/13/2020 | 340.97% | Morgan Stanley | $32 → $31 | Maintains | Equal-Weight |
| 08/10/2020 | 355.19% | Morgan Stanley | $27 → $32 | Maintains | Equal-Weight |
| 08/07/2020 | 824.61% | Raymond James | $46 → $65 | Maintains | Outperform |
| 06/18/2020 | 540.11% | SunTrust Robinson Humphrey | → $45 | Initiates Coverage On | → Buy |
| 05/11/2020 | 284.07% | Morgan Stanley | $30 → $27 | Maintains | Equal-Weight |
| 02/27/2020 | 483.21% | Raymond James | $44 → $41 | Maintains | Outperform |
| 02/21/2020 | 298.29% | Wells Fargo | → $28 | Initiates Coverage On | → Equal-Weight |
| 04/12/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 02/08/2019 | 326.74% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/18/2023 | 13.8% | 摩根大通 | →$8 | 升級 | 減重→中性 |
| 10/17/2023 | - | 康託·菲茨傑拉德 | 評級下調 | 超重→中性 | |
| 09/29/2023 | 141.82% | Stifel | $9→$17 | 升級 | 持有→購買 |
| 09/13/2023 | 99.15% | 康託·菲茨傑拉德 | →$14 | 重申 | 超重→超重 |
| 2023年08月29日 | 99.15% | 康託·菲茨傑拉德 | →$14 | 重申 | 超重→超重 |
| 08/03/2023 | 70.7% | 奧本海默 | →$12 | 重申 | 執行→執行 |
| 08/03/2023 | 170.27% | 查爾丹資本 | $22→$19 | 維護 | 買 |
| 2023/06/13 | 113.37% | 康託·菲茨傑拉德 | →$15 | 重申 | 超重→超重 |
| 2023/06/13 | 141.82% | 雷蒙德·詹姆斯 | →$17 | 升級 | 市場表現優於→ |
| 05/09/2023 | 70.7% | 奧本海默 | →$12 | 重申 | →性能 |
| 05/08/2023 | 13.8% | 加拿大皇家銀行資本 | $7→$8 | 維護 | 行業表現 |
| 05/08/2023 | 99.15% | 瑞士信貸 | $15→$14 | 維護 | 中性 |
| 05/08/2023 | 212.94% | 查爾丹資本 | →$22 | 重申 | →購買 |
| 02/23/2023 | 113.37% | 瑞士信貸 | $13→$15 | 維護 | 中性 |
| 02/23/2023 | 212.94% | 查爾丹資本 | $35→$22 | 維護 | 買 |
| 02/23/2023 | 42.25% | 加拿大皇家銀行資本 | $14→$10 | 維護 | 行業表現 |
| 02/01/2023 | 113.37% | 康託·菲茨傑拉德 | →$15 | 開始承保 | →超重 |
| 01/24/2023 | -0.43% | 摩根士丹利 | $8→$7 | 維護 | 體重不足 |
| 2023年1月23日 | -0.43% | SVB Leerink | $6→$7 | 維護 | 市場表現 |
| 2023年1月10日 | -14.65% | SVB Leerink | $7→$6 | 維護 | 市場表現 |
| 01/04/2023 | 412.09% | 富國銀行 | $50→$36 | 維護 | 超重 |
| 2022年12月13日 | 56.47% | 花旗集團 | →$11 | 開始承保 | →中性 |
| 12/06/2022 | 84.92% | 瑞士信貸 | →$13 | 假設 | →中性 |
| 2022年11月18日 | 113.37% | B of A證券 | $18→$15 | 維護 | 中性 |
| 2022年11月18日 | 397.87% | Truist證券 | $80→$35 | 維護 | 買 |
| 2022年11月18日 | 156.05% | 貝爾德 | $25→$18 | 維護 | 跑贏大盤 |
| 2022年11月18日 | 13.8% | 摩根士丹利 | $10→$8 | 維護 | 體重不足 |
| 2022年11月18日 | 99.15% | 加拿大皇家銀行資本 | $32→$14 | 維護 | 行業表現 |
| 2022年11月18日 | 70.7% | 奧本海默 | $28→$12 | 評級下調 | 超越→表現 |
| 2022年11月18日 | 84.92% | 瑞士信貸 | $25→$13 | 評級下調 | 跑贏→中性 |
| 2022年11月18日 | 397.87% | 查爾丹資本 | $43→$35 | 維護 | 買 |
| 2022年11月17日 | -0.43% | SVB Leerink | $14→$7 | 維護 | 市場表現 |
| 11/08/2022 | 42.25% | 摩根士丹利 | $15→$10 | 維護 | 體重不足 |
| 11/03/2022 | 355.19% | 加拿大皇家銀行資本 | $40→$32 | 維護 | 行業表現 |
| 11/03/2022 | 255.62% | 貝爾德 | $30→$25 | 維護 | 跑贏大盤 |
| 11/03/2022 | 511.66% | 查爾丹資本 | $60→$43 | 維護 | 買 |
| 11/03/2022 | 70.7% | SVB Leerink | $14→$12 | 維護 | 市場表現 |
| 09/29/2022 | 156.05% | B of A證券 | →$18 | 開始承保 | →中性 |
| 08/04/2022 | 141.82% | 巴克萊 | $16→$17 | 維護 | 等重 |
| 2022年05月24日 | 13.8% | 高盛 | $10→$8 | 維護 | 賣 |
| 05/09/2022 | 113.37% | 摩根士丹利 | $17→$15 | 維護 | 體重不足 |
| 04/12/2022 | 141.82% | 摩根士丹利 | $16→$17 | 維護 | 體重不足 |
| 02/25/2022 | 682.36% | 奧本海默 | $80→$55 | 維護 | 跑贏大盤 |
| 02/25/2022 | 753.49% | 查爾丹資本 | $75→$60 | 維護 | 買 |
| 02/25/2022 | 284.07% | SVB Leerink | $41→$27 | 維護 | 市場表現 |
| 01/06/2022 | 241.39% | 摩根士丹利 | $37→$24 | 維護 | 體重不足 |
| 10/19/2021 | 483.21% | SVB Leerink | →$41 | 開始承保 | →市場表現 |
| 09/24/2021 | 824.61% | Stifel | →$65 | 開始承保 | →保留 |
| 09/10/2021 | 1037.98% | 奧本海默 | $42→$80 | 升級 | →表現強於大盤 |
| 08/09/2021 | 1037.98% | Truist證券 | $45→$80 | 升級 | 持有→購買 |
| 08/05/2021 | 753.49% | Evercore ISI集團 | $20→$60 | 升級 | 表現遜於→強於 |
| 2021/05/10 | 426.32% | 摩根士丹利 | $40→$37 | 維護 | 體重不足 |
| 05/04/2021 | 468.99% | 加拿大皇家銀行資本 | →$40 | 開始承保 | →行業表現 |
| 04/16/2021 | 184.5% | 高盛 | →$20 | 開始承保 | →銷售 |
| 03/22/2021 | 725.04% | 瑞士信貸 | →$58 | 開始承保 | →跑贏大盤 |
| 03/02/2021 | 468.99% | 摩根士丹利 | $45→$40 | 維護 | 體重不足 |
| 03/01/2021 | 554.34% | 巴克萊 | →$46 | 評級下調 | 超重→等重 |
| 02/26/2021 | 540.11% | Truist證券 | →$45 | 評級下調 | 購買→Hold |
| 02/10/2021 | 995.31% | 查爾丹資本 | $55→$77 | 維護 | 買 |
| 2021/01/19 | 540.11% | 摩根士丹利 | $64→$45 | 評級下調 | 等重→減碼 |
| 01/08/2021 | - | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 12/16/2020 | 810.38% | 摩根士丹利 | $30→$64 | 維護 | 等重 |
| 12/10/2020 | 881.51% | 富國銀行 | $28→$69 | 升級 | 等重→超重 |
| 11/11/2020 | 326.74% | 摩根士丹利 | $31→$30 | 維護 | 等重 |
| 11/06/2020 | 753.49% | 雷蒙德·詹姆斯 | $65→$60 | 維護 | 跑贏大盤 |
| 11/03/2020 | 99.15% | 貝爾德 | →$14 | 開始承保 | →表現不佳 |
| 10/13/2020 | 340.97% | 摩根士丹利 | $32→$31 | 維護 | 等重 |
| 2020/08/10 | 355.19% | 摩根士丹利 | $27→$32 | 維護 | 等重 |
| 08/07/2020 | 824.61% | 雷蒙德·詹姆斯 | $46→$65 | 維護 | 跑贏大盤 |
| 06/18/2020 | 540.11% | SunTrust Robinson Humphrey | →$45 | 開始承保 | →購買 |
| 05/11/2020 | 284.07% | 摩根士丹利 | $30→$27 | 維護 | 等重 |
| 02/27/2020 | 483.21% | 雷蒙德·詹姆斯 | $44→$41 | 維護 | 跑贏大盤 |
| 02/21/2020 | 298.29% | 富國銀行 | →$28 | 開始承保 | →等重 |
| 2019年4月12日 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 2019年08月02日 | 326.74% | BTIG | →$30 | 開始承保 | →購買 |
What is the target price for Editas Medicine (EDIT)?
Editas Medicine的目標價格是多少(EDIT)？
The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by JP Morgan on October 18, 2023. The analyst firm set a price target for $8.00 expecting EDIT to rise to within 12 months (a possible 13.80% upside). 37 analyst firms have reported ratings in the last year.
摩根大通於2023年10月18日報道了Editas Medicine(納斯達克：EDIT)的最新目標價。這家分析公司將目標價定為8.00美元，預計EDIT將在12個月內上漲至13.80%(可能上漲13.80%)。去年有37家分析公司公佈了評級。
What is the most recent analyst rating for Editas Medicine (EDIT)?
Editas Medicine的最新分析師評級是什麼(EDIT)？
The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by JP Morgan, and Editas Medicine upgraded their neutral rating.
納斯達克(JP Morgan)提供了最新的分析師對Editas Medicine的評級，Editas Medicine上調了其中性評級。
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Editas Medicine的下一次分析師評級將於何時發佈或更新(EDIT)？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Editas Medicine的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Editas Medicine的最後一次評級是在2023年10月18日提交的，所以你應該預計下一次評級將在2024年10月18日左右的某個時候提供。
Is the Analyst Rating Editas Medicine (EDIT) correct?
分析師評級Editas Medicine(EDIT)正確嗎？
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a upgraded with a price target of $0.00 to $8.00. The current price Editas Medicine (EDIT) is trading at is $7.03, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Editas Medicine(EDIT)評級被上調，目標價從0.00美元到8.00美元。Editas Medicine(EDIT)目前的交易價格為7.03美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。